Recce Pharmaceuticals

Recce Pharmaceuticals Capital Intensity

The Capital Intensity Ratio of Recce Pharmaceuticals (RCE.AX) as of Nov 22, 2026 is 165.33 %. In the previous year, Capital Intensity Ratio was 126.67 % — a change of 30.52% (higher).

Capital Intensity

165.33 %

YoY

30.52%

Last updated:

Capital Intensity Ratio of Recce Pharmaceuticals is 2025 165.33 % . Capital Intensity Ratio of Recce Pharmaceuticals was 2024 126.67 % . It decreases by 30.52% higher compared to the previous year.

The Recce Pharmaceuticals Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
88.76 AUD
Jan 1, 2019
135.69 AUD
Jan 1, 2020
289.21 AUD
Jan 1, 2021
1,324.16 AUD
Jan 1, 2022
409.20 AUD
Jan 1, 2023
58.55 AUD
Jan 1, 2024
126.67 AUD
Jan 1, 2025
165.33 AUD
The Recce Pharmaceuticals Capital Intensity history
YEARCapital IntensityYoY
165.33 %+30.52%
126.67 %+116.35%
58.55 %-85.69%
409.20 %-69.10%
1,324.16 %+357.86%
289.21 %+113.14%
135.69 %+52.87%
88.76 %-91.56%
1,051.43 %-49.98%
2,101.83 %-52.01%
4,379.80 %+2,773.35%
152.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recce Pharmaceuticals stock

Capital Intensity Ratio of Recce Pharmaceuticals is 165.33 % in 2025.

Capital Intensity Ratio of Recce Pharmaceuticals changed from 126.67 % to 165.33 %, representing a 30.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Recce Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Recce Pharmaceuticals

All Key Metrics — Recce Pharmaceuticals